Radiopharm Theranostics Files 6-K Report
Ticker: RDPTF · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
TL;DR
Radiopharm Theranostics (RPT) filed a 6-K, standard foreign issuer report, no major news.
AI Summary
Radiopharm Theranostics Limited, a pharmaceutical preparations company, filed a Form 6-K on November 20, 2025. The filing is a report of a foreign private issuer for the month of November 2025. The company's principal executive office is located in Carlton South, Victoria, Australia.
Why It Matters
This filing indicates ongoing reporting requirements for Radiopharm Theranostics as a foreign private issuer, providing transparency to investors about its regulatory status.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 001-41621 (company) — SEC File Number
- Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (company) — Principal executive office address
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the registrant?
The registrant is Radiopharm Theranostics Limited.
When was this report filed?
The report was filed on November 20, 2025.
Where is the company's principal executive office located?
The company's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Does the registrant file annual reports under Form 20-F?
Yes, the registrant indicates it files or will file annual reports under cover of Form 20-F.
Filing Stats: 320 words · 1 min read · ~1 pages · Grade level 18 · Accepted 2025-11-20 06:18:37
Filing Documents
- ea0266560-6k_radio.htm (6-K) — 14KB
- ea026656001ex99-1_radio.htm (EX-99.1) — 27KB
- ea026656001ex99-2_radio.htm (EX-99.2) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 174KB
- ex99-1_002.jpg (GRAPHIC) — 382KB
- ex99-1_003.jpg (GRAPHIC) — 170KB
- ex99-1_004.jpg (GRAPHIC) — 231KB
- ex99-1_005.jpg (GRAPHIC) — 181KB
- ex99-1_006.jpg (GRAPHIC) — 94KB
- ex99-1_007.jpg (GRAPHIC) — 91KB
- ex99-1_008.jpg (GRAPHIC) — 232KB
- ex99-1_009.jpg (GRAPHIC) — 79KB
- ex99-1_010.jpg (GRAPHIC) — 237KB
- ex99-1_011.jpg (GRAPHIC) — 138KB
- ex99-1_012.jpg (GRAPHIC) — 131KB
- ex99-1_013.jpg (GRAPHIC) — 80KB
- ex99-1_014.jpg (GRAPHIC) — 239KB
- ex99-1_015.jpg (GRAPHIC) — 119KB
- ex99-1_016.jpg (GRAPHIC) — 101KB
- ex99-1_017.jpg (GRAPHIC) — 158KB
- ex99-1_018.jpg (GRAPHIC) — 102KB
- ex99-1_019.jpg (GRAPHIC) — 264KB
- ex99-1_020.jpg (GRAPHIC) — 148KB
- ex99-1_021.jpg (GRAPHIC) — 231KB
- ex99-1_022.jpg (GRAPHIC) — 171KB
- ex99-2_001.jpg (GRAPHIC) — 149KB
- ex99-2_002.jpg (GRAPHIC) — 293KB
- ex99-2_003.jpg (GRAPHIC) — 128KB
- 0001213900-25-112827.txt ( ) — 5915KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on November 20, 2025 titled: “Presentation to Annual General Meeting” “Results of Meeting” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Presentation to Annual General Meeting 99.2 Results of Meeting 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: November 20, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3